PVCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PVCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Provectus Biopharmaceuticals's share price is $0.13. Provectus Biopharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $-0.01. Hence, Provectus Biopharmaceuticals's PB Ratio of today is .
The historical rank and industry rank for Provectus Biopharmaceuticals's PB Ratio or its related term are showing as below:
During the past 13 years, Provectus Biopharmaceuticals's highest PB Ratio was 7.86. The lowest was 0.00. And the median was 0.58.
During the past 3 years, the average Book Value Per Share Growth Rate was 38.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 26.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Provectus Biopharmaceuticals was 39.40% per year. The lowest was -41.20% per year. And the median was -24.30% per year.
The historical data trend for Provectus Biopharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Provectus Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Provectus Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Provectus Biopharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Provectus Biopharmaceuticals's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 0.13 | / | -0.013 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Provectus Biopharmaceuticals (OTCPK:PVCT) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey Allen Morris | 10 percent owner | 1729 TRIANGLE PARK DR., MARYVILLE TN 37801 |
Webster Bailey | director | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
Heather Raines | officer: Chief Financial Officer | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
Edward Pershing | director | 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919 |
John Iii Lacy | director | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
John R Glass | officer: See Remarks | 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931 |
Bruce Horowitz | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Dominic Rodrigues | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Peter R Culpepper | officer: Interim CEO, CFO, COO | 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931 |
Eric Phd Wachter | director, officer: Chief Technology Officer | PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Jan Koe | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Smith Alfred E. Iv | director | 191 MAIN STREET, NEW CANAAN CT 06840 |
Kelly M Mcmasters | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Donald E Adams | 10 percent owner | 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401 |
Timothy Phd Scott | director, 10 percent owner, officer: President | PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-08-2022
By Value_Insider Value_Insider • 12-01-2022
By Marketwired • 04-16-2024
By Marketwired • 04-18-2024
By Marketwired • 06-28-2023
By Stock market mentor Stock market mentor • 01-09-2023
By PurpleRose PurpleRose • 08-17-2022
By Marketwired • 08-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.